HEADER TRANSCRIPTION 31-AUG-17 6AUG TITLE CRYSTAL STRUCTURE OF HUMAN PPARGAMMA LIGAND BINDING DOMAIN IN COMPLEX TITLE 2 WITH SR16832 COMPND MOL_ID: 1; COMPND 2 MOLECULE: PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: UNP RESIDUES 231-505; COMPND 5 SYNONYM: PPAR-GAMMA,NUCLEAR RECEPTOR SUBFAMILY 1 GROUP C MEMBER 3; COMPND 6 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: PPARG, NR1C3; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PET46 KEYWDS NUCLEAR RECEPTORS, TZDS, DRUG DESIGN, THERAPEUTIC TARGETS, KEYWDS 2 TRANSCRIPTION EXPDTA X-RAY DIFFRACTION AUTHOR J.SHANG,D.J.KOJETIN REVDAT 4 04-OCT-23 6AUG 1 LINK REVDAT 3 25-DEC-19 6AUG 1 REMARK REVDAT 2 09-JAN-19 6AUG 1 JRNL REVDAT 1 12-SEP-18 6AUG 0 JRNL AUTH J.SHANG,R.BRUST,S.A.MOSURE,J.BASS,P.MUNOZ-TELLO,H.LIN, JRNL AUTH 2 T.S.HUGHES,M.TANG,Q.GE,T.M.KAMEKENCKA,D.J.KOJETIN JRNL TITL COOPERATIVE COBINDING OF SYNTHETIC AND NATURAL LIGANDS TO JRNL TITL 2 THE NUCLEAR RECEPTOR PPAR GAMMA. JRNL REF ELIFE V. 7 2018 JRNL REFN ESSN 2050-084X JRNL PMID 30575522 JRNL DOI 10.7554/ELIFE.43320 REMARK 2 REMARK 2 RESOLUTION. 2.73 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : PHENIX 1.11.1_2575 REMARK 3 AUTHORS : PAUL ADAMS,PAVEL AFONINE,VINCENT CHEN,IAN REMARK 3 : DAVIS,KRESHNA GOPAL,RALF GROSSE-KUNSTLEVE, REMARK 3 : LI-WEI HUNG,ROBERT IMMORMINO,TOM IOERGER, REMARK 3 : AIRLIE MCCOY,ERIK MCKEE,NIGEL MORIARTY, REMARK 3 : REETAL PAI,RANDY READ,JANE RICHARDSON, REMARK 3 : DAVID RICHARDSON,TOD ROMO,JIM SACCHETTINI, REMARK 3 : NICHOLAS SAUTER,JACOB SMITH,LAURENT REMARK 3 : STORONI,TOM TERWILLIGER,PETER ZWART REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.73 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 45.56 REMARK 3 MIN(FOBS/SIGMA_FOBS) : 1.350 REMARK 3 COMPLETENESS FOR RANGE (%) : 85.1 REMARK 3 NUMBER OF REFLECTIONS : 15055 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 R VALUE (WORKING + TEST SET) : 0.207 REMARK 3 R VALUE (WORKING SET) : 0.198 REMARK 3 FREE R VALUE : 0.281 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 10.000 REMARK 3 FREE R VALUE TEST SET COUNT : 1506 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (IN BINS). REMARK 3 BIN RESOLUTION RANGE COMPL. NWORK NFREE RWORK RFREE REMARK 3 1 45.5677 - 6.0673 0.98 1471 164 0.1759 0.2552 REMARK 3 2 6.0673 - 4.8175 0.99 1448 160 0.1919 0.2641 REMARK 3 3 4.8175 - 4.2090 0.98 1421 159 0.1632 0.2325 REMARK 3 4 4.2090 - 3.8244 0.96 1381 154 0.1709 0.2491 REMARK 3 5 3.8244 - 3.5504 0.89 1302 143 0.1975 0.2786 REMARK 3 6 3.5504 - 3.3411 0.82 1164 130 0.2034 0.2975 REMARK 3 7 3.3411 - 3.1738 0.77 1105 123 0.2124 0.3017 REMARK 3 8 3.1738 - 3.0357 0.76 1090 122 0.2454 0.3695 REMARK 3 9 3.0357 - 2.9189 0.75 1063 117 0.2614 0.3231 REMARK 3 10 2.9189 - 2.8182 0.73 1039 116 0.2544 0.3846 REMARK 3 11 2.8182 - 2.7301 0.74 1065 118 0.2537 0.3304 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : NULL REMARK 3 SOLVENT RADIUS : 1.11 REMARK 3 SHRINKAGE RADIUS : 0.90 REMARK 3 K_SOL : NULL REMARK 3 B_SOL : NULL REMARK 3 REMARK 3 ERROR ESTIMATES. REMARK 3 COORDINATE ERROR (MAXIMUM-LIKELIHOOD BASED) : 0.410 REMARK 3 PHASE ERROR (DEGREES, MAXIMUM-LIKELIHOOD BASED) : 28.760 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 27.30 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 30.29 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 TWINNING INFORMATION. REMARK 3 FRACTION: NULL REMARK 3 OPERATOR: NULL REMARK 3 REMARK 3 DEVIATIONS FROM IDEAL VALUES. REMARK 3 RMSD COUNT REMARK 3 BOND : 0.009 4320 REMARK 3 ANGLE : 1.147 5813 REMARK 3 CHIRALITY : 0.051 668 REMARK 3 PLANARITY : 0.006 733 REMARK 3 DIHEDRAL : 6.035 2646 REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 NCS DETAILS REMARK 3 NUMBER OF NCS GROUPS : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 6AUG COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 01-SEP-17. REMARK 100 THE DEPOSITION ID IS D_1000229867. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 16-OCT-16 REMARK 200 TEMPERATURE (KELVIN) : 200 REMARK 200 PH : 7.6 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU MICROMAX-007 HF REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : MAR SCANNER 345 MM PLATE REMARK 200 INTENSITY-INTEGRATION SOFTWARE : IMOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 15056 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.730 REMARK 200 RESOLUTION RANGE LOW (A) : 45.561 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 85.1 REMARK 200 DATA REDUNDANCY : 1.800 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 10.4300 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : NULL REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: 1PRG REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 55.81 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.78 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.8M SODIUM CITRATE, 100MM MOPS, PH REMARK 280 7.6, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 46.30500 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 31.04000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 46.30500 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 31.04000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2, 3 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 3 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 2050 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 24740 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -13.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 APPLY THE FOLLOWING TO CHAINS: B REMARK 350 BIOMT1 2 1.000000 0.000000 0.000000 -46.30500 REMARK 350 BIOMT2 2 0.000000 1.000000 0.000000 31.04000 REMARK 350 BIOMT3 2 0.000000 0.000000 1.000000 0.00000 REMARK 375 REMARK 375 SPECIAL POSITION REMARK 375 THE FOLLOWING ATOMS ARE FOUND TO BE WITHIN 0.15 ANGSTROMS REMARK 375 OF A SYMMETRY RELATED ATOM AND ARE ASSUMED TO BE ON SPECIAL REMARK 375 POSITIONS. REMARK 375 REMARK 375 ATOM RES CSSEQI REMARK 375 HOH B 602 LIES ON A SPECIAL POSITION. REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 202 REMARK 465 GLN A 203 REMARK 465 LEU A 204 REMARK 465 ASN A 205 REMARK 465 PRO A 206 REMARK 465 LYS A 265 REMARK 465 HIS A 266 REMARK 465 ILE A 267 REMARK 465 THR A 268 REMARK 465 PRO A 269 REMARK 465 LEU A 270 REMARK 465 GLN A 271 REMARK 465 GLU A 272 REMARK 465 GLN A 273 REMARK 465 SER A 274 REMARK 465 TYR A 477 REMARK 465 GLY B 202 REMARK 465 GLN B 203 REMARK 465 LEU B 204 REMARK 465 ASN B 205 REMARK 465 PRO B 206 REMARK 465 GLN B 271 REMARK 465 GLU B 272 REMARK 465 GLN B 273 REMARK 465 SER B 274 REMARK 465 ASP B 462 REMARK 465 MET B 463 REMARK 465 SER B 464 REMARK 465 LEU B 465 REMARK 465 TYR B 477 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 SG CYS A 285 C02 BXG A 501 1.53 REMARK 500 NH2 ARG B 234 O SER B 332 1.57 REMARK 500 O HOH A 601 O HOH A 613 2.07 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 THR A 242 56.85 -65.68 REMARK 500 LYS A 244 109.26 80.36 REMARK 500 LYS A 301 -37.29 -33.36 REMARK 500 GLU A 343 5.27 56.04 REMARK 500 GLU A 378 72.07 54.56 REMARK 500 ASP A 396 6.49 -61.47 REMARK 500 GLU A 427 2.66 -65.87 REMARK 500 THR A 461 4.67 -64.73 REMARK 500 ASP A 475 -160.90 -67.47 REMARK 500 SER B 208 -75.65 18.85 REMARK 500 LEU B 237 -89.22 -79.84 REMARK 500 LYS B 240 -63.84 -104.02 REMARK 500 THR B 241 67.08 -67.22 REMARK 500 ASP B 243 -78.99 -46.39 REMARK 500 LYS B 244 106.98 -59.01 REMARK 500 HIS B 266 -1.14 -142.22 REMARK 500 ILE B 267 93.94 -53.98 REMARK 500 SER B 342 70.68 51.77 REMARK 500 LYS B 358 -116.18 47.27 REMARK 500 ASP B 362 53.50 -103.77 REMARK 500 PHE B 363 -64.41 -131.19 REMARK 500 LEU B 393 55.04 -94.92 REMARK 500 SER B 394 -80.69 -66.72 REMARK 500 THR B 459 -26.29 -155.02 REMARK 500 GLU B 460 96.14 -69.24 REMARK 500 TYR B 473 36.12 -98.49 REMARK 500 ASP B 475 -29.29 -173.82 REMARK 500 REMARK 500 REMARK: NULL REMARK 610 REMARK 610 MISSING HETEROATOM REMARK 610 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 610 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 610 I=INSERTION CODE): REMARK 610 M RES C SSEQI REMARK 610 BXG A 501 REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue BXG A 501 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue KNA A 502 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for Di-peptide BXG B 501 and CYS B REMARK 800 285 DBREF 6AUG A 203 477 UNP P37231 PPARG_HUMAN 231 505 DBREF 6AUG B 203 477 UNP P37231 PPARG_HUMAN 231 505 SEQADV 6AUG GLY A 202 UNP P37231 EXPRESSION TAG SEQADV 6AUG GLY B 202 UNP P37231 EXPRESSION TAG SEQRES 1 A 276 GLY GLN LEU ASN PRO GLU SER ALA ASP LEU ARG ALA LEU SEQRES 2 A 276 ALA LYS HIS LEU TYR ASP SER TYR ILE LYS SER PHE PRO SEQRES 3 A 276 LEU THR LYS ALA LYS ALA ARG ALA ILE LEU THR GLY LYS SEQRES 4 A 276 THR THR ASP LYS SER PRO PHE VAL ILE TYR ASP MET ASN SEQRES 5 A 276 SER LEU MET MET GLY GLU ASP LYS ILE LYS PHE LYS HIS SEQRES 6 A 276 ILE THR PRO LEU GLN GLU GLN SER LYS GLU VAL ALA ILE SEQRES 7 A 276 ARG ILE PHE GLN GLY CYS GLN PHE ARG SER VAL GLU ALA SEQRES 8 A 276 VAL GLN GLU ILE THR GLU TYR ALA LYS SER ILE PRO GLY SEQRES 9 A 276 PHE VAL ASN LEU ASP LEU ASN ASP GLN VAL THR LEU LEU SEQRES 10 A 276 LYS TYR GLY VAL HIS GLU ILE ILE TYR THR MET LEU ALA SEQRES 11 A 276 SER LEU MET ASN LYS ASP GLY VAL LEU ILE SER GLU GLY SEQRES 12 A 276 GLN GLY PHE MET THR ARG GLU PHE LEU LYS SER LEU ARG SEQRES 13 A 276 LYS PRO PHE GLY ASP PHE MET GLU PRO LYS PHE GLU PHE SEQRES 14 A 276 ALA VAL LYS PHE ASN ALA LEU GLU LEU ASP ASP SER ASP SEQRES 15 A 276 LEU ALA ILE PHE ILE ALA VAL ILE ILE LEU SER GLY ASP SEQRES 16 A 276 ARG PRO GLY LEU LEU ASN VAL LYS PRO ILE GLU ASP ILE SEQRES 17 A 276 GLN ASP ASN LEU LEU GLN ALA LEU GLU LEU GLN LEU LYS SEQRES 18 A 276 LEU ASN HIS PRO GLU SER SER GLN LEU PHE ALA LYS LEU SEQRES 19 A 276 LEU GLN LYS MET THR ASP LEU ARG GLN ILE VAL THR GLU SEQRES 20 A 276 HIS VAL GLN LEU LEU GLN VAL ILE LYS LYS THR GLU THR SEQRES 21 A 276 ASP MET SER LEU HIS PRO LEU LEU GLN GLU ILE TYR LYS SEQRES 22 A 276 ASP LEU TYR SEQRES 1 B 276 GLY GLN LEU ASN PRO GLU SER ALA ASP LEU ARG ALA LEU SEQRES 2 B 276 ALA LYS HIS LEU TYR ASP SER TYR ILE LYS SER PHE PRO SEQRES 3 B 276 LEU THR LYS ALA LYS ALA ARG ALA ILE LEU THR GLY LYS SEQRES 4 B 276 THR THR ASP LYS SER PRO PHE VAL ILE TYR ASP MET ASN SEQRES 5 B 276 SER LEU MET MET GLY GLU ASP LYS ILE LYS PHE LYS HIS SEQRES 6 B 276 ILE THR PRO LEU GLN GLU GLN SER LYS GLU VAL ALA ILE SEQRES 7 B 276 ARG ILE PHE GLN GLY CYS GLN PHE ARG SER VAL GLU ALA SEQRES 8 B 276 VAL GLN GLU ILE THR GLU TYR ALA LYS SER ILE PRO GLY SEQRES 9 B 276 PHE VAL ASN LEU ASP LEU ASN ASP GLN VAL THR LEU LEU SEQRES 10 B 276 LYS TYR GLY VAL HIS GLU ILE ILE TYR THR MET LEU ALA SEQRES 11 B 276 SER LEU MET ASN LYS ASP GLY VAL LEU ILE SER GLU GLY SEQRES 12 B 276 GLN GLY PHE MET THR ARG GLU PHE LEU LYS SER LEU ARG SEQRES 13 B 276 LYS PRO PHE GLY ASP PHE MET GLU PRO LYS PHE GLU PHE SEQRES 14 B 276 ALA VAL LYS PHE ASN ALA LEU GLU LEU ASP ASP SER ASP SEQRES 15 B 276 LEU ALA ILE PHE ILE ALA VAL ILE ILE LEU SER GLY ASP SEQRES 16 B 276 ARG PRO GLY LEU LEU ASN VAL LYS PRO ILE GLU ASP ILE SEQRES 17 B 276 GLN ASP ASN LEU LEU GLN ALA LEU GLU LEU GLN LEU LYS SEQRES 18 B 276 LEU ASN HIS PRO GLU SER SER GLN LEU PHE ALA LYS LEU SEQRES 19 B 276 LEU GLN LYS MET THR ASP LEU ARG GLN ILE VAL THR GLU SEQRES 20 B 276 HIS VAL GLN LEU LEU GLN VAL ILE LYS LYS THR GLU THR SEQRES 21 B 276 ASP MET SER LEU HIS PRO LEU LEU GLN GLU ILE TYR LYS SEQRES 22 B 276 ASP LEU TYR HET BXG A 501 24 HET KNA A 502 11 HET BXG B 501 24 HETNAM BXG 2-CHLORO-N-(6-METHOXYQUINOLIN-4-YL)-5-NITROBENZAMIDE HETNAM KNA NONANOIC ACID FORMUL 3 BXG 2(C17 H12 CL N3 O4) FORMUL 4 KNA C9 H18 O2 FORMUL 6 HOH *60(H2 O) HELIX 1 AA1 GLU A 207 PHE A 226 1 20 HELIX 2 AA2 THR A 229 THR A 238 1 10 HELIX 3 AA3 ASP A 251 ILE A 262 1 12 HELIX 4 AA4 GLU A 276 SER A 302 1 27 HELIX 5 AA5 GLY A 305 LEU A 309 5 5 HELIX 6 AA6 ASP A 310 ALA A 331 1 22 HELIX 7 AA7 ILE A 341 GLY A 344 5 4 HELIX 8 AA8 ARG A 350 SER A 355 1 6 HELIX 9 AA9 MET A 364 GLU A 378 1 15 HELIX 10 AB1 ASP A 380 LEU A 393 1 14 HELIX 11 AB2 ASN A 402 HIS A 425 1 24 HELIX 12 AB3 GLN A 430 LYS A 438 1 9 HELIX 13 AB4 LYS A 438 GLU A 460 1 23 HELIX 14 AB5 HIS A 466 ILE A 472 1 7 HELIX 15 AB6 SER B 208 PHE B 226 1 19 HELIX 16 AB7 THR B 229 LEU B 237 1 9 HELIX 17 AB8 ASP B 251 ILE B 262 1 12 HELIX 18 AB9 GLU B 276 ILE B 303 1 28 HELIX 19 AC1 ASP B 310 ALA B 331 1 22 HELIX 20 AC2 ARG B 350 SER B 355 1 6 HELIX 21 AC3 MET B 364 ALA B 376 1 13 HELIX 22 AC4 ASP B 380 LEU B 393 1 14 HELIX 23 AC5 ASN B 402 HIS B 425 1 24 HELIX 24 AC6 GLN B 430 ILE B 456 1 27 HELIX 25 AC7 PRO B 467 TYR B 473 1 7 SHEET 1 AA1 4 PHE A 247 ILE A 249 0 SHEET 2 AA1 4 GLY A 346 THR A 349 1 O PHE A 347 N ILE A 249 SHEET 3 AA1 4 GLY A 338 VAL A 339 -1 N VAL A 339 O MET A 348 SHEET 4 AA1 4 MET A 334 ASN A 335 -1 N ASN A 335 O GLY A 338 SHEET 1 AA2 3 PHE B 247 ILE B 249 0 SHEET 2 AA2 3 GLY B 346 THR B 349 1 O PHE B 347 N ILE B 249 SHEET 3 AA2 3 GLY B 338 ILE B 341 -1 N VAL B 339 O MET B 348 LINK SG CYS B 285 C02 BXG B 501 1555 1555 1.98 SITE 1 AC1 12 CYS A 285 GLN A 286 ARG A 288 SER A 289 SITE 2 AC1 12 HIS A 323 ILE A 326 TYR A 327 LEU A 330 SITE 3 AC1 12 PHE A 363 HIS A 449 LEU A 453 TYR A 473 SITE 1 AC2 7 GLY A 284 CYS A 285 PHE A 287 ARG A 288 SITE 2 AC2 7 ILE A 341 SER A 342 GLU A 343 SITE 1 AC3 18 ILE B 281 PHE B 282 GLN B 283 GLY B 284 SITE 2 AC3 18 GLN B 286 PHE B 287 ARG B 288 SER B 289 SITE 3 AC3 18 ILE B 326 TYR B 327 LEU B 330 VAL B 339 SITE 4 AC3 18 LEU B 340 PHE B 363 MET B 364 HIS B 449 SITE 5 AC3 18 LEU B 453 LEU B 476 CRYST1 92.610 62.080 118.450 90.00 102.34 90.00 C 1 2 1 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.010798 0.000000 0.002362 0.00000 SCALE2 0.000000 0.016108 0.000000 0.00000 SCALE3 0.000000 0.000000 0.008642 0.00000